Project Grant K01AG081542

Award Date 8/1/24
Completion Date 7/31/29
Dollars Obligated $258K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is focused on assessing whether genetic risk variants for Alzheimer's disease (AD) have a pleiotropic effect on sleep. The primary objectives are to conduct in silico variant-to-gene mapping analysis to identify potential shared genetic factors underlying AD and sleep phenotypes, and to use CRISPR in zebrafish models to directly evaluate the impact of putative AD...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $383,400 to Dr. Minjee Kim at Northwestern University to investigate the role of sleep disturbance as a potentially modifiable determinant of cognitive impairment and Alzheimer's disease. The award will fund Dr. Kim's research to: 1) examine associations between sleep disturbance, cognitive function, self-care capacity, and health status in middle-aged adults; 2) develop sleep disturbance...
This $1,955,041 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into the relationship between sleep, pericytes, and Alzheimer's disease pathology. The Medical University of South Carolina will investigate whether pericytes, cells that regulate cerebral blood flow and blood-brain barrier permeability, mediate the effects of sleep disruption on Alzheimer's disease progression. Specifically, the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $684,924 to Northwestern University to conduct research on the relationship between the noradrenergic (NA) system, sleep quality, and cognitive function in older adults with insomnia. The project aims to systematically characterize central and peripheral measures of the NA system and assess their association with sleep quality and cognitive performance in older adults with insomnia, as well as...
This federal Project Grant award of $442,938, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research at the University of California, San Francisco (UCSF) to investigate the relationship between sleep, memory, and aging. The key objectives are to: 1) characterize how aging affects sleep patterns required for memory consolidation and synaptic plasticity during long-term memory formation; and 2) determine how upregulating the unfolded protein response can...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,498,158 to Synaptic Health LLC to develop a novel closed-loop feedback neuromodulation system to improve slow wave sleep in Alzheimer's disease patients. The goal of this Phase I project is to create a testable prototype that can sense sleep architecture and provide peripheral neuromodulation stimulation to individuals over 65, a high-risk group for Alzheimer's disease. Successful...
This $7.72 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The Seattle Institute for Biomedical and Clinical Research will define the role of post-traumatic brain injury sleep disruption and glymphatic dysfunction in the development of Alzheimer's disease and chronic traumatic encephalopathy neuropathology. Over three years, the grantee and three sub-awardees will...
This $1,505,109 Project Grant awarded by the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to identify undiagnosed Alzheimer's disease (AD) in non-Hispanic White, Hispanic/Latino, and non-Hispanic African American populations. The project will leverage electronic health records and genetic data to develop disease trajectory models and polygenic risk scores to detect undiagnosed AD, while addressing the issue of underdiagnosis in underserved...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $129,659 to The Johns Hopkins University to conduct a longitudinal study examining the relationship between physical activity, sleep, brain network connectivity/microstructure, and cognitive resilience in aging and preclinical Alzheimer's disease. The research aims to identify modifiable lifestyle factors and neuroimaging biomarkers that may enhance cognitive resilience and help elucidate the...
The National Institute on Aging (NIA) awarded Brigham & Women's Hospital Inc. a $2,576,936 Project Grant under the Aging Research federal grant program (CFDA 93.866) to characterize the variability in sleep spindle activity across a population and evaluate the use of sleep spindle dynamics as biomarkers for Alzheimer's disease, mild cognitive impairment, and trisomy 21. The 3-year project will develop statistical models and methods to analyze sleep spindle patterns and their relationship...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $258,498.00 to the University of California, Los Angeles (UCLA) to investigate the biological pathways linking sleep health to Alzheimer's disease and cognitive decline. The key objectives are to:

  1. Use a multi-omics approach to analyze methylation and metabolomics data associated with short sleep and insomnia among a high-risk Hispanic population, and compare the results to Alzheimer's disease biomarkers.

  2. Determine the direct relationship between partial sleep deprivation and the presence of Alzheimer's disease biomarkers through an experimental study.

  3. Integrate the findings to decipher the causal effect of short sleep and insomnia on Alzheimer's disease and identify mediating biomarkers.

This research aims to address critical gaps in understanding the biological mechanisms connecting sleep health issues to Alzheimer's disease risk, which can inform future therapeutic strategies, especially for populations facing health disparities. The award period runs from August 1, 2024 to July 31, 2029.

Generated 7/1/25, 3:51 AM